arrow
K

Kristian Reich

university medical center hamburg eppendorf
H指数:104
被引数:4.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND

特应性皮炎中度至重度患者接受特立珠单抗治疗长达6年的长期安全性与有效性:开放标签扩展试验ECZTEND的最终结果

2026-02-050
OAAI
Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis

中重度特应性皮炎成人患者中曲尼司特长达4年的疗效

2025-11-011
OAAI
Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials

特应性皮炎患者中特立洛金单抗的安全性(随访长达4.5年):一项八项临床试验的整合分析

2025-11-011
OAAI
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial

Sonelokimab,一种抑制IL-17A/IL-17F的纳米抗体,用于活动性银屑病关节炎:一项随机、安慰剂对照的2期试验

2025-10-060
OAAI
Effects of a Gel Containing the Defined Microalgae Extract Spiralin® on the Skin Microbiome and Clinical Activity in Atopic Dermatitis: A Double-Blind, Intraindividual Vehicle-Controlled Proof-Of-Concept Study

含特定微藻提取物Spiralin®的凝胶对特应性皮炎皮肤微生物组和临床活性的影响:一项双盲、个体内赋形剂对照的概念验证研究

2025-09-010
OA
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis
2024-09-014
OAAI
Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials

tralokinumab治疗治疗4.5年特应性皮炎患者的安全性: 对8项临床试验的最新综合分析

2024-08-080
PRE
Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials

tralokinumab治疗治疗4.5年特应性皮炎患者的安全性: 对8项临床试验的最新综合分析

2024-02-070
PRE
Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control

持续tralokinumab治疗成人中度至重度特应性皮炎超过4年提供长期的疾病控制

2024-02-071
PRE
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)

Brodalumab与Guselkumab在对Ustekinumab反应不足的中度至重度银屑病患者中的比较: 一项随机,多中心,双盲4期试验 (COBRA)

2024-02-011
OAAI